Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx’s SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan’s AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX’s valuation.
Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you’re searching for “VolitionRx quarterly earnings report 10-Q filing” or need “VolitionRx insider trading Form 4 transactions” before market open, we have you covered. Key documents are mapped to the insights they contain:
- 10-K / annual report — cash-burn trends, patent status, and pipeline milestones in one “VolitionRx annual report 10-K simplified” summary.
- 10-Q / quarterly earnings — segment spending, licensing revenue and trial enrollment metrics with concise “VolitionRx earnings report filing analysis”.
- 8-K — real-time alerts on material events; think “VolitionRx 8-K material events explained” minutes after filing.
- Form 4 — “VolitionRx Form 4 insider transactions real-time” so you can track executive stock moves the moment they file.
- DEF 14A proxy — drill into “VolitionRx proxy statement executive compensation” without digging through appendices.
Use Stock Titan’s AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics—“understanding VolitionRx SEC documents with AI” has never been easier. Schedule custom alerts, export tables for models and compare “VolitionRx executive stock transactions Form 4” against peer trends, all from one screen.
New England Realty Associates Limited Partnership (ticker: NEN) filed an amended Form 4 reporting a very small disposition of partnership interests by President and Director Ronald Brown on 30-Jun-2025.
- Units sold back to partnership: 0.3 General Partner Units (indirect) and 5.8 Class B Limited Partner Units (direct), coded “J” to indicate the transaction was executed under the partnership’s 2020 equity repurchase program.
- Pricing: The transaction price was disclosed as $2,311.01, derived from the contemporaneous buy-back price of $77.03 per Depositary Receipt (each equal to 1/30th of a Class A Unit).
- Post-trade ownership: Brown retains 291.4 General Partner Units indirectly (via a closely-held corporation of which he owns 75%) and 5,536.1 Class B Units directly, meaning less than 1% of his economic stake was tendered.
The filing signals routine participation in the partnership’s authorized repurchase plan rather than a market sale, and the volumes are immaterial relative to Brown’s overall holdings and to NEN’s total outstanding units.
Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.
The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.
Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.
The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.
Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.
The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.
Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.
The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.
Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.
The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.
Form 144 filed for Roblox Corporation (NYSE: RBLX) discloses that insider Matthew D. Kaufman intends to sell up to 6,000 common shares on or about 3 July 2025 through Charles Schwab & Co. at an aggregate market value of $615,480. The block equals roughly 0.001 % of Roblox’s 629,990,658 shares outstanding.
The shares derive from equity compensation awards—restricted stock units that vested on 20 May 2023 (4,960 shares) and 20 Aug 2023 (1,040 shares). No cash consideration was paid when the awards vested.
Kaufman has been a frequent seller. During the past three months he executed six transactions totaling 51,021 shares for approximately $4.07 million in gross proceeds (dates: 3 Apr, 5 May, 15 May, 20 May, 5 Jun, 20 Jun 2025).
Under Rule 144, insiders must aggregate sales with other affiliates and certify that they possess no undisclosed material adverse information. The filing is LIVE, indicating an imminent transaction subject to customary Rule 144 volume and manner-of-sale limits.
While the upcoming sale is immaterial to Roblox’s float, ongoing disposals by a corporate insider can be monitored by investors as a potential sentiment signal.
VolitionRx held its Annual Meeting on June 18, 2025, where stockholders approved several significant proposals. The most notable change was the approval of a Certificate of Second Amendment to increase authorized shares from 175 million to 325 million shares of common stock ($0.001 par value).
Key meeting outcomes include:
- Election of eight board members, including CEO Cameron Reynolds, who received strong support with 36.1M votes
- Ratification of Sadler, Gibb & Associates as independent auditors with overwhelming approval (51.2M votes in favor)
- Approval of executive compensation through a non-binding advisory vote (34.4M votes in favor)
- Strong support for the share authorization increase with 49.4M votes in favor
The meeting had 51.6 million shares represented out of 100.7 million outstanding shares. The amendment became effective upon filing with Delaware's Secretary of State on June 18, 2025, marking a significant expansion in the company's potential capital structure.